You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Apolipoprotein A I antibody (HRP) (ab35992)

Submit an Abreview Submit a Question

Overview

  • Product nameAnti-Apolipoprotein A I antibody (HRP)See all Apolipoprotein A I primary antibodies ...
  • Description
    Sheep polyclonal to Apolipoprotein A I (HRP)
  • ConjugationHRP
  • Conjugation notesThe periodate method was used to conjugate this antibody to HRP.
  • SpecificityThis antibody binds purified human apolipoprotein A1 and human HDL. It does not react with other human plasma proteins, including albumin or immunoglobulin fractions of human serum, neither does it cross react with human apolipoprotein B, LDL and VLDL.
  • Tested applicationsELISA, WB more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Apolipoprotein A-1 (Human)

Properties

Applications

Our Abpromise guarantee covers the use of ab35992 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ELISA
WB
  • Application notesELISA: 1/1000 - 1/6000. For use as a detection antibody with OPD as a substrate. Using TMB, higher titres can be used.
    WB: 1/100 - 1/600. Predicted molecular weight: 31 kDa.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.

    • Target

    • FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
    • Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
    • Involvement in diseaseDefects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
      Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
      Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
      Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
    • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
    • Post-translational
      modifications      Palmitoylated.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted.

      • Target information above from: UniProt accession P02647 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt
    • Database links
      • Alternative names
          Apo AI antibodyApo-AI antibodyApoA I antibody
          ApoA-I antibodyAPOA1 antibodyAPOA1/APOC3 fusion gene antibodyAPOA1_HUMAN antibodyApolipoprotein A I precursor antibodyApolipoprotein A-I(1-242) antibodyApolipoprotein A1 antibodyApolipoprotein AI antibodyApolipoprotein of high density lipoprotein antibodyApolipoproteinAI antibodyBrp14 antibodyLtw1 antibodyLvtw1 antibodyMGC117399 antibodySep1 antibodySep2 antibody
        see all

      References for Anti-Apolipoprotein A I antibody (HRP) (ab35992)

      ab35992 has not yet been referenced specifically in any publications.

      Publishing research using ab35992 ? Please let us know so that we can cite the reference in this datasheet

      Product Wall

      Submit an Abreview for ab35992 Submit a Question for ab35992

      There are currently no Abreviews or Questions for ab35992.
      Please use the links above to contact us or submit feedback about this product.

      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"